Transcatheter aortic valve replacement in heart failure

Eur J Heart Fail. 2024 Feb;26(2):460-470. doi: 10.1002/ejhf.3151. Epub 2024 Jan 31.

Abstract

Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The use of transcatheter aortic valve replacement (TAVR) has become the preferred therapy for most patients with AS and concomitant HF. With its instant afterload reduction, TAVR offers patients with HF significant haemodynamic benefits, with corresponding changes in left ventricular structure and improved mortality and quality of life. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear. The purpose of this review is to describe the association between TAVR and outcomes in patients with HF, particularly in the setting of left ventricular systolic dysfunction, acute HF, and right ventricular systolic dysfunction, and to highlight areas for future research.

Keywords: Aortic stenosis; Ejection fraction; Heart failure; Transcatheter aortic valve intervention; Transcatheter aortic valve replacement.

Publication types

  • Review

MeSH terms

  • Aortic Valve / surgery
  • Aortic Valve Stenosis* / complications
  • Aortic Valve Stenosis* / surgery
  • Heart Failure* / complications
  • Heart Failure* / surgery
  • Humans
  • Quality of Life
  • Risk Factors
  • Severity of Illness Index
  • Transcatheter Aortic Valve Replacement*
  • Treatment Outcome
  • Ventricular Function, Left